Loading…
Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of severe aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation which transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp. is based in Toowong, Australia.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $0M | $0M | - | - | - | - |
| 2024 | $0M | $0M | $0M | - | - | -100.0% | - |
| 2023 | $3M | $-46M | $-46M | $-37M | -243.5% | -14.6% | - |
| 2022 | $3M | $-29M | $-31M | $-31M | -338.3% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 3.20 | 2.73 | 0 | 0 |
| Cost Of Revenue | 2.90 | 1.86 | 0 | 0 |
| Gross Profit | 0.30 | 0.88 | 0 | 0 |
| Operating Expense | 31.79 | 47.53 | 0 | 0 |
| Operating Income | -31.49 | -46.66 | 0 | 0 |
| EBITDA | -29.14 | -45.54 | 0 | 0 |
| EBIT | -29.92 | -46.70 | 0 | 0 |
| Pretax Income | -30.56 | -46.76 | 0 | 0 |
| Tax Provision | 0 | 0 | 0 | 0 |
| Net Income | -30.56 | -46.02 | 0 | 0 |
| Net Income Common Stockholders | -30.56 | -46.02 | 0 | 0 |
| Total Expenses | 34.69 | 49.39 | 0 | 0 |
| Interest Expense | 0.65 | 0.07 | 0 | 0 |
| Interest Income | 0.21 | 0.43 | 0 | 0 |
| Research And Development | 17.59 | 30.89 | 0 | 0 |
| Selling General And Administration | 15.21 | 17.05 | 0 | 0 |
| Normalized EBITDA | -30.50 | -44.28 | 0 | 0 |
| Normalized Income | -31.92 | -44.76 | 0 | 0 |
| Basic EPS | -2.26 | -2.94 | -3.77 | -2.55 |
| Diluted EPS | -2.26 | -2.94 | -3.77 | -2.55 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Tax Rate For Calcs | 0 | 0 | 0 | 0 |
| Total Unusual Items | 1.36 | -1.26 | 0 | 0 |
| Total Unusual Items Excluding Goodwill | 1.36 | -1.26 | 0 | 0 |
| Net Income From Continuing Operation Net Minority Interest | -30.56 | -46.02 | 0 | 0 |
| Reconciled Depreciation | 0.77 | 1.16 | 0 | 0 |
| Reconciled Cost Of Revenue | 2.35 | 1.02 | 0 | 0 |
| Net Interest Income | -0.44 | 0.36 | 0 | 0 |
| Net Income From Continuing And Discontinued Operation | -30.56 | -46.02 | 0 | 0 |
| Total Operating Income As Reported | -31.11 | -48.14 | 0 | 0 |
| Diluted Average Shares | 13.36 | 15.61 | 20.25 | 36.91 |
| Basic Average Shares | 13.36 | 15.61 | 20.25 | 36.91 |
| Diluted NI Availto Com Stockholders | -30.56 | -46.02 | 0 | 0 |
| Minority Interests | 0 | 0.74 | 0 | 0 |
| Net Income Including Noncontrolling Interests | -30.56 | -46.76 | 0 | 0 |
| Net Income Continuous Operations | -30.56 | -46.76 | 0 | 0 |
| Other Income Expense | 1.36 | -0.47 | 0 | 0 |
| Other Non Operating Income Expenses | 0 | 0.79 | 0 | 0 |
| Special Income Charges | 0 | -0.63 | 0 | 0 |
| Gain On Sale Of Ppe | 0 | -0.50 | 0 | 0 |
| Other Special Charges | 0 | 0.13 | 0 | 0 |
| Gain On Sale Of Security | 1.36 | -0.63 | 0 | 0 |
| Net Non Operating Interest Income Expense | -0.44 | 0.36 | 0 | 0 |
| Interest Expense Non Operating | 0.65 | 0.07 | 0 | 0 |
| Interest Income Non Operating | 0.21 | 0.43 | 0 | 0 |
| Other Operating Expenses | -1.24 | -0.72 | 0 | 0 |
| Depreciation Amortization Depletion Income Statement | 0.23 | 0.31 | 0 | 0 |
| Depreciation And Amortization In Income Statement | 0.23 | 0.31 | 0 | 0 |
| Selling And Marketing Expense | 0.81 | 1.09 | 0 | 0 |
| General And Administrative Expense | 14.41 | 15.96 | 0 | 0 |
| Other Gand A | 6.60 | 5.26 | 0 | 0 |
| Insurance And Claims | 0.64 | 0.84 | 0 | 0 |
| Salaries And Wages | 7.17 | 9.86 | 0 | 0 |
| Operating Revenue | 3.20 | 2.73 | 0 | 0 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Anteris Technologies Global Corp.this co. | AVR | $574M | - | -2950.00 | - | -6.11 |
| CorMedix Inc. | CRMD | $591M | 3.67 | 1.46 | 40.2% | 3.38 |
| Prothena Corporation plc | PRTA | $585M | - | 2.09 | -87.0% | -1.56 |
| Zevra Therapeutics, Inc. | ZVRA | $572M | 7.16 | 3.56 | 53.8% | -2457.74 |
| Phreesia, Inc. | PHR | $569M |
| 234.25 |
| 1.69 |
| 0.7% |
| 29.02 |
| NeuroPace, Inc. | NPCE | $562M | - | 29.17 | -112.8% | -35.19 |
| Rigel Pharmaceuticals, Inc. | RIGL | $540M | 1.50 | 1.37 | 93.8% | 3.43 |
| Embecta Corp. | EMBC | $536M | 5.72 | -0.84 | -14.6% | 6.16 |
| SI-BONE, Inc. | SIBN | $528M | - | 2.93 | -10.6% | -25.11 |
| Peer Median | - | 5.72 | 1.89 | -5.0% | 0.91 | |